FACTOID # 24: Looking for table makers? Head to Mississippi, with an overwhlemingly large number of employees in furniture manufacturing.
 
 Home   Encyclopedia   Statistics   States A-Z   Flags   Maps   FAQ   About 
 
WHAT'S NEW
 

SEARCH ALL

FACTS & STATISTICS    Advanced view

Search encyclopedia, statistics and forums:

 

 

(* = Graphable)

 

 


Encyclopedia > Celgene
Celgene
Type Public NASDAQCELG
Founded 1986
Headquarters Summit, New Jersey
Industry Healthcare, Biotechnology, Pharmaceutical company
Products THALOMID®, REVLIMID®
Employees 1,287 (2007)
Website www.celgene.com

Celgene Corporation NASDAQCELG is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. As of January 1, 2007, the company had 1,287 full-time employees, 725 of whom were engaged primarily in research and development activities.[1] The company's major products are THALOMID® (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and REVLIMID® (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID® is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both THALOMID® and REVLIMID® are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene also receives royalties from Novartis Pharma AG on sales of the entire RITALIN® family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). Image File history File links Metadata No higher resolution available. ... This article does not cite any references or sources. ... NASDAQ in Times Square, New York City. ... Nickname: Location of Summit within Union County and state of New Jersey Coordinates: , Country USA State New Jersey County Union Settled 1710 Incorporation as Township March 23, 1869 Incorporation as City March 8, 1899 Government  - Type Faulkner Act Council-Manager  - Mayor Jordan Glatt  - City Administrator Christopher Cotter Area  - City 15. ... Health care or healthcare is one of the worlds largest and fastest growing professions. ... The structure of insulin Biotechnology is technology based on biology, especially when used in agriculture, food science, and medicine. ... A pharmaceutical company, or drug company, is a commercial business whose focus is to research, develop, market and/or distribute drugs, most commonly in the context of healthcare. ... This article is about work. ... A website (alternatively, Web site or web site) is a collection of Web pages, images, videos and other digital assets that is hosted on one or several Web server(s), usually accessible via the Internet, cell phone or a LAN. A Web page is a document, typically written in HTML... NASDAQ in Times Square, New York City. ... Nickname: Location of Summit within Union County and state of New Jersey Coordinates: , Country USA State New Jersey County Union Settled 1710 Incorporation as Township March 23, 1869 Incorporation as City March 8, 1899 Government  - Type Faulkner Act Council-Manager  - Mayor Jordan Glatt  - City Administrator Christopher Cotter Area  - City 15. ... This article is about the drug. ... Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. ... The three major single chromosome mutations; deletion (1), duplication (2) and inversion (3). ... Novartis Suffern Yes plant is the Swiss companys sole pharmaceutical production facility in the U.S. Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland that manufactures mainstream products such as Benefiber (a fiber supplement) and Lamisil (a foot fungus medicine). ... DISCLAIMER Please remember that Wikipedia is offered for informational use only. ...


Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank. A cord blood bank is a place that stores umbilical cord blood for future use. ...

Contents

History

In 1986, Celgene, originally a unit of the Celanese Corporation, was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation.


In July 1998, Celgene received approval from the FDA to market THALOMID® for the acute treatment of the cutaneous manifestations of moderate to severe ENL.


In April 2000, Celgene reached an agreement with Novartis Pharma AG to license d-MPH, Celgene's chirally pure version of RITALIN®. The FDA subsequently granted approval to market d-MPH, or FOCALIN®, in November 2001.


In August 2000, Celgene acquired Signal Pharmaceuticals, Inc., a privately held company that searches for and develops pharmaceuticals that regulate disease-related genes. Signal Pharmaceuticals, Inc. now operates as Celgene Research San Diego, a wholly owned subsidiary of Celgene Corporation.


In December 2002, Celgene acquired Anthrogenesis, a privately held New Jersey-based biotherapeutics company and cord blood banking business, which is developing technology for the recovery of stem cells from placental tissues following the completion of full-term successful pregnancies. Anthrogenesis now operates as Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene.


In December 2005, Celgene received approval from the FDA to market REVLIMID® for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. The three major single chromosome mutations; deletion (1), duplication (2) and inversion (3). ...


In May 2006, Celgene received approval for THALOMID® in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.


In June 2007, Celgene received full marketing authorization for REVLIMID® in combination with dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy by the European Commission.


Products

Product Portfolio
Brand Name Drug Name(s) Indication Date Approved (USA)[2] Partner
Revlimid® lenalidomide transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities 12-27-2005  
Revlimid® lenalidomide (in combination with dexamethasone) treatment of multiple myeloma patients who have received at least one prior therapy 06-29-2006  
Thalomid® thalidomide acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences 07-16-1998  
Thalomid® thalidomide (in combination with dexamethasone) treatment of patients with newly diagnosed multiple myeloma 05-25-2006 GlaxoSmithKline
Alkeran® melphalan palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary 01-17-1964 GlaxoSmithKline
Alkeran® melphalan hydrochloride the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate 11-18-1992 GlaxoSmithKline
Focalin® dexmethlyphenidate hydrochloride attention deficit hyperactivity disorder (ADHD) in children and adolescents 11-13-2001 Novartis
Focalin XR® dexmethlyphenidate hydrochloride attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults 05-26-2005 Novartis

Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. ... Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. ... Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid hormones. ... This article is about the drug. ... This article is about the drug. ... Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid hormones. ... GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a British based pharmaceutical, biological, and healthcare company. ... Melphalan hydrochloride ( Alkeran®) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents. ... GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a British based pharmaceutical, biological, and healthcare company. ... Melphalan hydrochloride (trade name Alkeran) is a chemotherapy drug belonging to the class of nitrogen mustard alkylating agents. ... GlaxoSmithKline plc (LSE: GSK NYSE: GSK) is a British based pharmaceutical, biological, and healthcare company. ... DISCLAIMER Please remember that Wikipedia is offered for informational use only. ... Novartis Suffern Yes plant is the Swiss companys sole pharmaceutical production facility in the U.S. Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland that manufactures mainstream products such as Benefiber (a fiber supplement) and Lamisil (a foot fungus medicine). ... DISCLAIMER Please remember that Wikipedia is offered for informational use only. ... Novartis Suffern Yes plant is the Swiss companys sole pharmaceutical production facility in the U.S. Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland that manufactures mainstream products such as Benefiber (a fiber supplement) and Lamisil (a foot fungus medicine). ...

References

“Securities and Exchange Commission” redirects here. ... Year 2007 (MMVII) is the current year, a common year starting on Monday of the Gregorian calendar and the AD/CE era. ... is the 246th day of the year (247th in leap years) in the Gregorian calendar. ... hi “FDA” redirects here. ... Year 2007 (MMVII) is the current year, a common year starting on Monday of the Gregorian calendar and the AD/CE era. ... is the 246th day of the year (247th in leap years) in the Gregorian calendar. ...

External links


 
 

COMMENTARY     


Share your thoughts, questions and commentary here
Your name
Your comments

Want to know more?
Search encyclopedia, statistics and forums:

 


Press Releases |  Feeds | Contact
The Wikipedia article included on this page is licensed under the GFDL.
Images may be subject to relevant owners' copyright.
All other elements are (c) copyright NationMaster.com 2003-5. All Rights Reserved.
Usage implies agreement with terms, 1022, m